Latest Dimebolin Stories

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that David Hung, M.D., president and chief executive officer, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, at 11:15 a.m. Eastern Time at the Millennium Broadway Hotel in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer. A live...

Forest Laboratories has presented positive Phase III data of a once-daily extended-release formulation of Namenda for Alzheimer's disease. The study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28mg once-daily extended-release formulation of Namenda (memantine HCl) compared to placebo in outpatients with moderate to severe Alzheimer's disease already being treated with a cholinesterase inhibitor (donepezil, galantamine or rivastigmine). In the study,...

CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimer's therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago. A related study showed that taking antidementia drugs appears to have a positive impact on extending lifespan in those with Alzheimer's. These reports included: Eighteen-month data...

To: NATIONAL EDITORS Contact: Alzheimers Association media line: +1-312-335-4078, media@alz.org; ICAD 2008 press room, July 27-31: +1-312-949-3253 - Plus, Taking Antidementia Drugs Extends Lifespan Three Years in Alzheimers - CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimers therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimers Association International Conference on...

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced new data showing that its investigational drug Dimebon continues to produce broad, clinically meaningful benefits in Alzheimer's disease patients after long-term dosing, and appears to operate through a novel mechanism of action. These data were presented today in a podium session and two poster sessions at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago....

By Jeremy Laurance Scientists were amazed when a 20-year-old hay fever drug was found to be highly effective in treating dementia. Jeremy Laurance reports on a startling discovery and asks what it could mean for sufferers A hundred years after Alzheimer's disease was discovered, a cure for the degenerative condition that strips sufferers of their memory and personality remains a dream. The main advances have been in drugs to control symptoms such as agitation and restlessness. Restoring...

By Jeremy Laurance Scientists were amazed when a 20-year-old hay fever drug was found to be highly effective in treating dementia. Jeremy Laurance reports on a startling discovery A hundred years after Alzheimer's disease was discovered, a cure for the degenerative condition that strips sufferers of their memory and personality remains a dream. The main advances have been in drugs to control symptoms such as agitation and restlessness. Restoring memory and cognitive ability has proved much...

CONTROLLING Alzheimer's disease has come a small step nearer after a study found a drug "significantly improved" patients' symptoms. On average people treated with Dimebon showed marked improvement in memory, thinking, behaviour and their ability to conduct simple daily activities such as eating. And the drug continued to reduce Alzheimer's symptoms further over a 12-month period - something no currently-approved medication can do. Dimebon's manufacturer, San Francisco-based Medivation,...

A potential new weapon against Alzheimer's is nothing to sneeze at because it's a hay fever medication, British doctors said. The antihistamine dimebon improved brain function and memory in patients with early- to mid-stage Alzheimer's, The Sun reported Friday. The Alzheimer's Research Trust, which assists many of the 500,000 British Alzheimer's patients, told the British newspaper no approved drug resulted in the improvements seen with Dimebon. Dr. Rachelle Doody, who led research in...

SAN FRANCISCO, July 17 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease: memory and thinking,...